218 related articles for article (PubMed ID: 9890493)
21. Thyroid suppression and medical ablation for differentiated thyroid cancer.
Dunn JT
Arch Otolaryngol Head Neck Surg; 1986 Nov; 112(11):1207-9. PubMed ID: 3755995
[TBL] [Abstract][Full Text] [Related]
22. Encapsulated insular carcinoma of the thyroid arising in graves' disease: report of a case and review of the literature.
Foroughi F; Saadat N; Salehian MT
Int J Surg Pathol; 2012 Dec; 20(6):636-9. PubMed ID: 22689614
[TBL] [Abstract][Full Text] [Related]
23. Well differentiated thyroid cancer.
Kinder BK
Curr Opin Oncol; 2003 Jan; 15(1):71-7. PubMed ID: 12490765
[TBL] [Abstract][Full Text] [Related]
24. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
25. Metastatic papillary thyroid carcinoma presenting as a primary renal neoplasm.
Graham LD; Roe SM
Am Surg; 1995 Aug; 61(8):732-4. PubMed ID: 7618817
[TBL] [Abstract][Full Text] [Related]
26. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.
Lin JD; Chao TC; Chen ST; Huang YY; Liou MJ; Hsueh C
Surg Oncol; 2007 Aug; 16(2):107-13. PubMed ID: 17600699
[TBL] [Abstract][Full Text] [Related]
27. [Metastatic renal tumor originating from thyroid cancer: a case report].
Arakaki R; Okada Y; Terada N; Kaneko Y; Nishimura K
Hinyokika Kiyo; 2010 Dec; 56(12):701-4. PubMed ID: 21273810
[TBL] [Abstract][Full Text] [Related]
28. The management of metastatic differentiated thyroid carcinoma.
Sherman SI
Rev Endocr Metab Disord; 2000 Apr; 1(3):165-71. PubMed ID: 11705002
[No Abstract] [Full Text] [Related]
29. Advances in the management of differentiated thyroid cancer with follicular cell strain.
Ben Slimène F; Mhiri A; Ben Ali M; Slimène H; Ben Raies N; Karboua E; Schlumberger M
Tunis Med; 2016 Mar; 94(3):168-71. PubMed ID: 27575497
[TBL] [Abstract][Full Text] [Related]
30. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
31. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy.
Kalender E; Zeki Celen Y; Elboga U; Deniz Demir H; Yilmaz M
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):328-31. PubMed ID: 23084016
[TBL] [Abstract][Full Text] [Related]
32. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
33. Minimally invasive follicular thyroid cancer: treat as a benign or malignant lesion?
Robinson A; Schneider D; Sippel R; Chen H
J Surg Res; 2017 Jan; 207():235-240. PubMed ID: 27979483
[TBL] [Abstract][Full Text] [Related]
34. Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report.
Ogawa Y; Sugawara T; Seki H; Sakuma T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):302-5. PubMed ID: 16794352
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
36. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
[TBL] [Abstract][Full Text] [Related]
37. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
McHenry CR; Sandoval BA
Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
[TBL] [Abstract][Full Text] [Related]
38. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
39. [Differentiated thyroid cancers].
Gorgone S; Campennì A; Calbo E; Catalfamo A; Sciglitano P; Sofia L; Niceta M; Borzì R; Calbo L
G Chir; 2009; 30(1-2):26-9. PubMed ID: 19272228
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
